Across TCGA pan-cancer cohorts, UBE2G2 mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated UBE2G2 data layer compared with 24 for mass-spec protein and 2 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher UBE2G2 mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated UBE2G2 expression acts as an unfavorable survival marker, although some lineages such as CCRCC and LSCC show a favorable association.

CCRCC, PDAC, and LSCC are the cancer types where UBE2G2 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	DFS	Tertile	II,III,IV	0.928	0.105	.006	41	view →
PDAC	DFS	Median	III,IV	0.166	0.552	.003	25	view →
LSCC	DFS	Quartile	All	1.000	0.851	.018	7	view →
LUAD	DFS	Median	III,IV	0.690	0.305	.038	2	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

Exploration

Same gene, other analysis: UBE2G2 tumor-vs-normal RNA expression · all UBE2G2 data types